
Roche withdraws checkpoint blocker from the market
Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...

Step Pharma presents promising cancer treatment
Since September 2022, STP938, the cancer inhibitor developed by Step Pharma SAS, has been undergoing clinical trials for the treatment of T and B...

Germany’s Curevac offers common shares
In addition to these ordinary shares, Tübingen-based CureVac is enticing investors to give up another 15% of the number of ordinary shares under the...

Novo Holdings invests into standardisation of LC-MS-based proteomics
Novo Holdings, the investment arm of Nordisk A/S has invested €40m in the eight-years-old clinical proteomics specialist Ecosep Aps to benefit from...

Vitestro raises €12m in Series A financing
California-based Sonder Capital led the Series A financing round alongside existing investors and new private investors. According to...

Evidence of deliberate climate damage
For decades, some members of the fossil fuel industry tried to convince the public that a causative link between fossil fuel use and climate warming...

Upping sustainability in pharma packaging
From glass vials, over cardboard applications, and biodegradable containers, at the PHARMAPACK Europe 2023 taking place on February 1st and 2nd in...